Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03766334
Other study ID # TJ-T1DM-CGM-001
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date December 5, 2018
Est. completion date December 31, 2023

Study information

Verified date March 2024
Source Huazhong University of Science and Technology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Approximately 80 patients will be enrolled in the study from China and randomized in a 1:1 ratio to one of the 2 treatment arms:diabetes diet+highland barley diet; or diabetes diet. Study treatment will continue for 12 weeks. The primary efficacy measure is the change in MAGE from continuous glucose monitoring system at 12 weeks. The study consists of 3 periods: a 1-week screening (period A), a 8-day run-in period (period B) and a 12-week treatment period (period C). Continuous glucose monitoring system will be used in baseline and endpoint.


Description:

This is a prospective, randomized, open-label comparison of the effects and safety of barley meal plus diabetes diet on blood glucose fluctuations in patients with type 1 diabetes (T1DM) using multiple daily insulin injections (MDI). , parallel test. About 80 patients with T1DM were enrolled in the preliminary trial. During the lead-in period, no interventions were given to the patient's diet from day 1 to day 4, and diabetes diet education and guidance were given from day 5 to day 8, depending on the patient's blood glucose and diet. Personalization of habits, weights, and activities, etc., establish a diabetes diet. At the end of the lead-in period, patients were randomly divided into two treatment groups according to the ratio of 1:1: Observation group: Diabetes diet + barley diet. (The barley meal group diet was formulated according to the diabetes diet, but each meal was replaced with 20g barley nutrition powder and other calories instead of part of the diet. In the control group: Diabetes diet; dietary treatment after randomization will continue for 12 weeks. From the induction period to the treatment period 6 days, treatment period 10-12 weeks


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 31, 2023
Est. primary completion date October 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. type 1 diabetes patients with disease duration more than one year 2. HbA1c =7.0 % and < 11.0 % 3. Men and women (non-pregnant and using a medically approved birthcontrol method) aged = 18 and = 65 years 4. BMI = 18 and = 26 kg/m2 Exclusion Criteria: 1. Type 2 diabetes or other specific types of diabetes 2. Pregnancy, preparation for pregnancy, lactation and women of childbearing age incapable of effective contraception methods 3. Uncooperative subject because of various reasons 4. Abnormal liver function, glutamic-pyruvic transaminase (ALT) and glutamic-oxaloacetic transaminase (AST) > twice the upper limits of normal 5. Impairment of renal function, serum creatinine: = 133mmol/L for female,= 135mmol/L for male 6. Serious chronic gastrointestinal diseases 7. Edema 8. Serious heart diseases, such as cardiac insufficiency (level III or more according to NYHA), acute coronary syndrome and old myocardial infraction 9. Blood pressure: Systolic blood pressure (SBP) = 180mmHg and/or diastolic blood pressure (DBP) = 110mmHg 10. White blood count (WBC) < 4.0×109/L or platelet count (PLT) < 90×109/L,or definite anemia (Hb:< 120g/L for male, < 110g/L for female), or other hematological diseases 11. Endocrine system diseases, such as hyperthyroidism and hypercortisolism 12. Experimental drug allergy or frequent hypoglycemia 13. Psychiatric disorders, drug or other substance abuse 14. Diabetic ketoacidosis and hyperosmolar nonketotic coma requiring insulin therapy 15. Stressful situations such as surgery, serious trauma and so on 16. Chronic hypoxic diseases such as pulmonary emphysema and pulmonary heart disease 17. Combined use of drugs effecting glucose metabolism such as glucocorticoid Tumor, especially bladder tumor and/or family history of bladder tumor and/or long-term hematuria

Study Design


Intervention

Dietary Supplement:
Highland Barley Diet
Highland Barley Diet(20g, thrice-daily)

Locations

Country Name City State
China Tongji Hospital, Tongji Medical College, Huazhong University of Science and technology Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Huazhong University of Science and Technology

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Average blood glucose fluctuations at endpoint and baseline Objective to investigate the effect of combination diabetes diet and highland barley diet on glucose variability in insufficient control patients with type 1 diabetes. from baseline to 12-week endpoint
Secondary Glycated hemoglobin(endpoint)-Glycated hemoglobin(baseline) Objective to investigate the effect of combination diabetes diet and highland barley diet on glucose control in patients with type 1 diabetes. from baseline to 12-week endpoint
Secondary insulin dose(endpoint)-insulin dose(baseline) Objective to investigate the effect of combination diabetes diet and highland barley diet on insulin dose in patients with type 1 diabetes. from baseline to 12-week endpoint
Secondary Quality of life assessment scale SF-36(endpoint)-Quality of life assessment scale SF-36(baseline) Objective to investigate the effect of combination diabetes diet and highland barley diet on life quality in patients with type 1 diabetes. from baseline to 12-week endpoint
Secondary Body mass index(endpoint)-Body mass index(baseline) Objective to investigate the effect of combination diabetes diet and highland barley diet on BMI in patients with type 1 diabetes. from baseline to 12-week endpoint
Secondary beta-cell function at endpoint and baseline Objective to investigate the effect of combination diabetes diet and highland barley diet on beta-cell function in patients with type 1 diabetes. from baseline to 12-week endpoint
Secondary Waist circumference(endpoint)-Waist circumference(baseline) Objective to investigate the effect of combination diabetes diet and highland barley diet on waist circumference in patients with type 1 diabetes. from baseline to 12-week endpoint
See also
  Status Clinical Trial Phase
Completed NCT03623113 - The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes N/A
Withdrawn NCT03396484 - Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes Phase 2
Completed NCT03117998 - Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus Phase 2
Recruiting NCT03369821 - EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)
Completed NCT03202732 - DiabetesFlex - Patient Involvement and Patient-reported Outcome Measures in Type 1 Diabetes N/A
Completed NCT03704818 - Dapagliflozin Effects on Hypoglycemia Phase 1
Recruiting NCT03864991 - Lifestyle Changes and Glycemic Control in T1D N/A
Completed NCT03725657 - Correlation Between Exercise and Insulin Dose in a Camp for Pediatric Type 1 Patients
Completed NCT02985866 - The International Diabetes Closed Loop (iDCL) Trial: Protocol 1 N/A
Completed NCT03003806 - Evaluation of the Dreamed Advisor Pro for Automated Insulin Pump Setting Adjustments in Children and Adolescents With Type 1 Diabetes- The Advice4U Pro Study N/A
Withdrawn NCT04147637 - FreeStyle Libre Plus Bluetooth Transmitter Adjunct: Can This Improve Glucose Accuracy and Reduce Burden of Hypoglycaemia N/A
Completed NCT03970889 - Real-time Reminders To Decrease Late or Missed Meal Boluses N/A
Recruiting NCT04589325 - Ixekizumab Diabetes Intervention Trial (I-DIT) Phase 2
Completed NCT03367390 - A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM) Phase 1
Completed NCT03738852 - Mechanisms for Restoration of Hypoglycemia Awareness Early Phase 1
Completed NCT03406585 - Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes Phase 1/Phase 2
Completed NCT03859856 - Ovarian Reserve in Diabetes Mellitus
Withdrawn NCT04102202 - BOL-DP-o-05 as an Add-On Treatment of Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Phase 1/Phase 2
Terminated NCT03353792 - Using an Artificial Pancreas System in Older Adult Type 1 Diabetes Mellitus Patients N/A
Recruiting NCT03811470 - China Diabetes Registry by Metabolic Management Center